Final results of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving <i>BRCA1/2</i> mutation carriers, sporadic ovarian, and castration resistant prostate cancer (CRPC).
Caroline O. Michie, Shahneen Sandhu, William R. Schelman, L. Rhoda Molife, George Wilding, Aurelius Omlin, Vikram Kansra, David G. Brooks, Robert E. Martell, Stanley B. Kaye, Johann S. de Bono, Robert M. Wenham (2013). Final results of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving <i>BRCA1/2</i> mutation carriers, sporadic ovarian, and castration resistant prostate cancer (CRPC).. , 31(15_suppl), DOI: https://doi.org/10.1200/jco.2013.31.15_suppl.2513.
